How ElevateBio plans to create portfolio of cell, gene therapy newcos with $150M MPM, F2-led round

Led by Alexion, bluebird veterans, ElevateBio launches to build internal manufacturing capabilities and spin out cell and gene therapy companies

With $150 million in series A funding and an executive team led by Alexion and bluebird veterans, ElevateBio emerged from stealth on Monday with plans to accelerate cell and gene therapy discovery and development by building companies with access to fully integrated process development and manufacturing capacity, and then connecting them

Read the full 513 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers